Related Experiment Videos
[Metabolic interactions of denaverine]
Die Pharmazie
|October 1, 1985
Summary
Denaverine (Spasmalgan) acts as a phenobarbital-type enzyme inducer in rats, shortening hexobarbital sleeping time. This suggests potential drug interactions with repeated denaverine use.
Area of Science:
- Pharmacology
- Biochemistry
- Toxicology
Context:
- Investigating the metabolic effects of denaverine (Spasmalgan) in female Wistar rats.
- Understanding the impact of drug pretreatment on liver enzyme activity and drug metabolism.
Purpose:
- To determine if denaverine induces liver microsomal enzymes.
- To assess the dose-dependent effects of denaverine on specific enzyme activities and drug metabolism pathways.
- To predict potential drug interactions associated with denaverine therapy.
Summary:
- Pretreatment with denaverine dose-dependently shortened hexobarbital sleeping time in rats.
- Denaverine increased aminophenazone-N-demethylation, p-nitroanisole-O-demethylation, cytochrome P-450 concentration, and NADPH-cytochrome-c-reductase activity.
- No significant changes were observed in p-nitrophenetol-O-dealkylation or p-nitrophenol-glucuronidation, indicating a specific induction profile.
Impact:
- Denaverine functions as a phenobarbital-type inducer of microsomal enzymes.
- The findings suggest a risk of drug interactions with repeated denaverine administration in combination therapies.
- Highlights the importance of considering enzyme induction when prescribing denaverine concurrently with other medications.